Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw.
Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw.
复制标题
与颌骨坏死有关的非双膦酸盐药物的生理学和药理学。
DOI：
--
复制
发表时间：
2012
期刊：
影响因子：
--
通讯作者：
M. Troeltzsch
中科院分区：
文献类型：
--
作者：
M. Troeltzsch;T. Woodlock;S. Kriegelstein;T. Steiner;K. Messlinger;M. Troeltzsch
接受癌症化疗的患者寿命更长，生活质量更好，他们在治疗期间和治疗后都需要牙科护理。自2003年马克思和2008年Ruggiero和Woo发现以来，双膦酸盐与药物相关性颌骨骨坏死（ONJ）相关。最近的文献表明，与用于癌症治疗的非双膦酸盐药物有类似的相关性。地舒单抗是一种破骨细胞抑制剂，用于骨科和肿瘤学，其引起ONJ的速率与静脉注射双膦酸盐相当。病例报告和药物机构记录表明ONJ与用于治疗许多常见癌症的新血管生成抑制剂贝伐单抗和舒尼替尼之间存在相关性。这3种药物的药理机制似乎不同，但对骨代谢的共同影响可能发生在易感宿主中。本文根据目前的科学认识，探讨了这些药物可能导致ONJ的机制。美国口腔颌面外科医师学会提供了关于双膦酸盐相关ONJ管理的详细建议，我们建议也应用于Denosumab、贝伐珠单抗和舒尼替尼暴露患者的管理。
Patients undergoing cancer chemotherapy are living longer and with better quality of life, and they require dental care both during and after their treatments. Bisphosphonates have been associated with drug-related osteonecrosis of the jaw (ONJ) since the discoveries of Marx in 2003 and Ruggiero and Woo in 2008. Recent literature has indicated a similar association with nonbisphosphonate drugs used in cancer therapy. Denosumab, an osteoclast inhibitor with applications in orthopedics and oncology, causes ONJ at a rate comparable to that for intravenously administered bisphosphonates. Case reports and drug agency records have indicated a correlation between ONJ and the neoangiogenesis inhibitors bevacizumab and sunitinib, which are used to treat many common cancers. The pharmacologic mechanisms of these 3 drugs appear distinct, yet a common effect on bone metabolism may occur in susceptible hosts. This review explores the mechanisms of these drugs that could lead to ONJ, according to current scientific understanding. The American Academy of Oral and Maxillofacial Surgeons has provided detailed recommendations for the management of bisphosphonate-related ONJ, which we suggest should also be applied in the management of patients with exposure to denosumab, bevacizumab and sunitinib.
影响因子：
18.6
作者：
Zelkha SA;Freilich RW;Amar S
通讯作者：
Amar S